192 results about "Peptidase P" patented technology

Provided herein are compounds of formula (I), or pharmaceutically acceptable salts or deuterated forms thereof, wherein ring A, R1, R2, R3, R4, and m are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I) or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in the treatment of a disease that is treatable by administration of a DPP1 inhibitor.

Provided herein are compounds of formulae (I) - (IX), or pharmaceutically acceptable salts or deuterated forms thereof as defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I) - (IX) or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I) - (IX) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in the treatment of a disease that is treatable by administration of a DPP1 inhibitor.

The invention relates to a protein combination for influencing the growth rate of yeast and the expression quantity of foreign proteins. After genes in a peptidase A1 family, a peptidase M1 family, a peptidase M18 family, a peptidase M28 family, a peptidase S54 family, a peptidase S10 family, a peptidase S16 family, a peptidase S14 family and a peptidase S8 family and protein defect related genes are knocked out as transcription activating factors, the growth rate can be increased, and the expression quantity of foreign proteins can be increased.

The invention provides a rehmannia fermented extract, a composition as well as a preparation method and application of the rehmannia fermented extract and the composition, and belongs to the technical field of biological medicines. According to the invention, raw dark green tea and rehmannia are fermented by using a single strain of eurotium cristatum to respectively obtain a raw dark green tea fermentation extract and a rehmannia fermentation extract. Experiments prove that the two extracts have a relatively good inhibition effect on dipeptidyl peptidase-4 when being independently used; furthermore, the two extracts are combined, and animal experiments prove that the composition has relatively good inhibitory activity on intestinal tract and excrement dipeptidyl peptidase-4 and also has a hypoglycemic effect.

Provided herein are compounds of formulae (I)-(IX), or pharmaceutically acceptable salts or deuterated forms thereof as defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I)-(IX) or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I)-(IX) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in the treatment of a disease that is treatable by administration of a DPP1 inhibitor.

The invention discloses a micromolecular bioluminescent probe capable of being used for monitoring in vivo / in vitro dipeptidyl peptidase IV in real time and a preparation method and application thereof.The probe is marked as DPP4-PD, during preparation, N-[t-butyloxycarbonyl] glycyl-L-proline and 6-amino-2-benzothiazole formonitrile serve as starting materials and then react with L-cysteine hydrochloric acid, and finally Boc is removed. The synthesis raw materials are easy to obtain, operation is simple, and popularization is easy. The micromolecular bioluminescence probe provided by the invention can specifically respond to DPP4 enzyme in vivo / in vitro in real time; and the probe has the remarkable advantages of high selectivity, high sensitivity, high stability, high biological safety, high signal-to-noise ratio (S / N) and the like during imaging, and has wide application prospects in the fields of pathological research, efficacy evaluation and new drug research and development.

Provided are: a compound defined by chemical formula 1; a stereoisomer thereof; a tautomer thereof; and pharmaceutically acceptable salts of the compound, the stereoisomer, and the tautomer. The compound according to the present invention can inhibit the activity of the USP1 enzyme. In chemical formula 1, R1 to R4 and [the symbol A in chemical formula 1] are as defined in the present specification.

The present invention relates to an oral care composition comprising a peptidase or lactonase, preferably a peptidase and a lactonase, use of said composition in medicine, use of said composition in treatment of oral disease, methods of treatment comprising administering said composition to a human subject, methods of preventing or removing oral biofilm comprising contacting an oral biofilm with said composition, methods for reducing the risk of oral biofilm formation, and kits of parts comprising said composition.

This invention discloses a quantitative detection kit for arginine peptidase, a qualitative detection kit for arginine peptidase, and their usage methods. The quantitative detection kit utilizes the specific substrate Nα-benzoyl-DL-arginine-4-ylbenzamide hydrochloride, which can be hydrolyzed by arginine peptidase to 4-ylbenzamide. 4-ylbenzamide has a maximum absorption peak at 405 nm, and the specific arginine peptidase activity can be rapidly detected at room temperature using spectrophotometry. The qualitative kit utilizes the specific substrate Nα-benzoyl-DL-arginine-β-naphthamide hydrochloride, which can be hydrolyzed by arginine peptidase to p-β-naphthamide. β-naphthamide combines with 4-(dimethylamino)cinnamaldehyde to form a compound that is visible to the naked eye as a pink color. The disulfide bond cleaving agent cuts the mucus disulfide bonds, exposing bacterial enzyme sites, and the synergistic effect of the enzyme activator enhances the reaction rate of arginine peptidase hydrolysis of the substrate, significantly improving the detection sensitivity of arginine peptidase in tongue coating samples.

The present disclosure provides modified AAV vectors which express a tripeptidyl peptidase 1 (TPPl) in subject. Aspects of the disclosure provide a modified adeno associated virus 1 (AAV1) vector comprising a capsid protein that comprises a targeting peptide and a nucleic acid molecule comprising a sequence encoding the modified AAV genome comprising a replication (rep) gene, a capsid (cap) gene, and a tripeptidyl peptidase 1 (TPP1) transgene.

Described herein is a new method for treating diseases such as non-alcoholic fatty liver disease and non-alcoholic steatohepatitis with a growth hormone secretagogue alone or in combination with a drug selected from a dipeptidyl peptidase-4 antagonist, a glucagon-like peptide receptor agonist, a thiazolidinedione, a sodium glucose transport protein 2 antagonist, and metformin. Compositions relating to the same are also provided.

Disclosed herein are vaccine constructs for producing a virus-like particle (VLP) capable of raising an immune response to an immunogen, and uses thereof, wherein the constructs comprise nucleic acid sequences encoding an immunogen and a polyprotein, wherein the polyprotein comprises two or more viral structural proteins, wherein at least two of the two or more viral structural proteins are separated by a signal peptidase sequence such that, when the polyprotein is expressed in a host cell, the signal peptidase sequence undergoes host cell peptidase-dependent cleavage to liberate the two or more viral structural proteins, thereby allowing the liberated structural proteins to self-assemble into a VLP carrying the immunogen.

Provided herein are compounds of Formulae (I), (II), (III), and (III-d). Also provided herein are methods of preparation of Formulae (I), (II), and (III-d). Further provided herein are methods of functionalizing or sequencing a peptide by reaction of compounds of Formula (III-d) with peptidases.

The present invention relates to a pharmaceutical composition for treating peptic gastric ulcer and a preparation method thereof, belonging to the field of biotechnology. The pharmaceutical composition contains chicken gizzard-membrane peptide, pumpkin seed extract, complex bacteria, white hyacinth bean flower extract and bletilla striata extract; the chicken gizzard-membrane peptide contains the products obtained by successively subjecting chicken gizzard-membrane to fractional enzymolysis with pepsin, chymotrypsin and keratinase; the pumpkin seed extract contains the products obtained by subjecting pumpkin seeds to co-enzymolysis with cellulase and pectinase and then successively to fractional enzymolysis with pepsin, nattokinase and aminopeptidase; the complex bacteria contain the co-fermentation bacteria of Lactobacillus acidophilus, Bifidobacterium and Lactobacillus casei; the white hyacinth bean flower extract is an ethanol percolation extract; the bletilla striata extract contains the products obtained by subjecting bletilla striata tubers to co-enzymolysis with cellulase and pectinase and then successively to fractional enzymolysis with pepsin, bromelain and serrapeptase. The various components are used in combination, having a good therapeutic effect on gastric ulcer, quickly and efficiently repairing gastric mucosa, and being safe and free of side effects.

The present invention relates to an oral care composition comprising a peptidase or lactonase, preferably a peptidase and a lactonase, use of said composition in medicine, use of said composition in treatment of oral disease, methods of treatment comprising administering said composition to a human subject, methods of preventing or removing oral biofilm comprising contacting an oral biofilm with said composition, methods for reducing the risk of oral biofilm formation, and kits of parts comprising said composition.

The invention discloses a polypeptide as well as preparation and application thereof, and belongs to the technical field of active peptides. According to the present invention, three active peptides are prepared from walnut meal protein, the amino acid sequences of the three polypeptides are respectively Leuu-Pro-Gln-Phe (LPQF), Leuu-Pro-Ser-Phe (LPSF) or Vla-Pro-Phe-Pro (VPFP), and the detection results show that the three polypeptides have inhibition activity on dipeptidyl peptidase-IV (DPP-IV), such that the three polypeptides can be used for preparing the blood sugar reducing drug.

The application belongs to the technical field of biotechnology, and particularly relates to application of albumin polypeptide gel beads in a product for treating or preventing sarcopenia. Egg white protein is used as raw material to extract protein, and albumin dipeptide-based peptidase-IV inhibitory peptide is prepared through a biological enzymolysis method. Bioinformatics analysis is used to screen out the inhibitory peptide TPYMFP, and the IC50 value of the inhibitory peptide TPYMFP for dipeptide-based peptidase-IV reaches 3.12 ± 0.49 mmol / L. Further, the optimal preparation conditions of sodium alginate SA and carboxymethyl chitosan CMCS-based gel beads CMCS / SA / TPYMFP are explored. When the SA concentration is 1.5% (w / v), the CMCS concentration is 0.5% (w / v), and the CaCl2 concentration is 1% (w / v), the polypeptide encapsulation rate is increased to 98.26% ± 0.25%. It is verified that the albumin polypeptide gel beads have good pH response characteristics, and efficient protection and intestinal target delivery of the sarcopenia inhibitory peptide are realized. The albumin polypeptide gel beads are applied to preparation of a product for treating or preventing sarcopenia, or in preparation of a related product for increasing muscle mass and strength.

The utility model relates to the technical field of peptide enzymolysis, in particular to a preparation device for enzymolysis extraction of small molecule peptides, which comprises an enzymolysis tank, a heat preservation sleeve is nested and connected on the outer surface of the enzymolysis tank, an auger shaft is rotatably connected in the enzymolysis tank, and a rotating shaft is fixedly connected at the upper end of the auger shaft in the enzymolysis tank. According to the utility model, the angle of the hinge rod is changed, and the fixed seat further drives the scraper to be close to the inner wall of the enzymolysis tank, so that the inner wall of the enzymolysis tank can be scraped through the scraper at the later stage of enzymolysis; the inner wall of the enzymolysis tank is prevented from being scraped all the time, the abrasion degree of the scraping plate is reduced, the positions of the first stirring blade and the second stirring blade are adjustable, raw materials and enzymes at different positions can be stirred conveniently, the stirring efficiency of the device is improved, and meanwhile after the outer surface of the scraping plate is abraded, the unabraded scraping plate can make contact with the inner wall of the enzymolysis tank.

The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.

The invention relates to a pharmaceutical composition for reducing dentin hypersensitivity and a preparation method thereof, and belongs to the technical field of biological medicine, the pharmaceutical composition comprises chanterelle extract, rabdosia rubescens leaf extract, eggshell membrane protein peptide and bifidobacterium thermophile fermentation extract; the cantharellus cibarius extract is obtained by sequentially performing enzymolysis on cantharellus cibarius through compound enzyme, ginger protease and serratipeptidase and purifying enzymatic hydrolysate through an AB-8 macroporous resin column. The rabdosia rubescens leaf extract is obtained by ultrasonically extracting rabdosia rubescens leaves with an ethanol water solution and purifying an extracting solution with a composite filler adsorption column. The eggshell membrane protein peptide is obtained by carrying out enzymolysis on a shell membrane by virtue of ginger protease and ficin and purifying an enzymatic hydrolysate by virtue of a G-25 sephadex column. The fermentation extract of the bifidobacterium thermophilus is obtained by purifying fermentation liquor of the bifidobacterium thermophilus through an SP agarose gel FF column. All the components are compounded according to a specific ratio and have a synergistic effect, so that the dentin hypersensitivity can be relieved safely in a multi-effect manner.

Provided are fusion proteins that inactivate coronaviruses and uses thereof. The fusion proteins herein comprise an ACE2 peptidase domain comprising the amino acid sequence set forth in SEQ ID NO: 1 directly or via a linker connected to a coronavirus polypeptide therapeutic that targets the HR1 domain. The fusion proteins are broad-spectrum, highly potent, and can inactivate viruses at an early, free stage.

The application discloses a method and application of knocking down ubiquitin-specific peptidase 7 protein, and belongs to the field of biological medicine. The method for knocking down the USP7 protein comprises: specifically inhibiting the expression of USP7 in endothelial cells through gene intervention, and the gene intervention means comprises shRNA, siRNA or recombinant virus carrier-mediated USP7 expression down-regulation. Further provided is a USP7 knockdown reagent for preparing a drug for treating endothelial cell inflammation or a cardiovascular disease, in particular, the USP7 knockdown reagent is a USP7 knockdown virus carrier containing a Cdh5 promoter; the cardiovascular disease comprises heart failure, myocardial infarction or ischemic cardiomyopathy. The application specifically knocks down the expression of USP7 in endothelial cells through gene intervention, significantly improves the migration, tube formation capacity and reduces the apoptosis of the endothelial cells, repairs endothelial dysfunction, the USP7 knockdown virus carrier is used for preparing a drug for treating a cardiovascular disease, and has important clinical value.

This invention provides a fermented extract of Rehmannia glutinosa, a composition thereof, its preparation method, and its application, belonging to the field of biomedical technology. This invention obtains fermented extracts of black tea and Rehmannia glutinosa by fermenting black tea and Rehmannia glutinosa with a single strain of *Aspergillus cristatus*. Experiments have verified that both extracts, used alone, have good inhibitory effects on dipeptidyl peptidase-4. Further, combining the two extracts and verifying through animal experiments, shows that they have good inhibitory activity against dipeptidyl peptidase-4 in the intestine and feces, while also exhibiting a hypoglycemic effect.

Provided herein are methods of treating Neuronal Ceroid Lipofuscinosis (CLN2) disease in a subject less than 3 years old. In exemplary embodiments, the method comprises administering to the subject a formulation comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) in an amount effective to treat the CLN2 disease in the subject. Also provided are methods of delaying the onset of CLN2 disease, or a symptom thereof, in a subject less than 3 years old. In exemplary embodiments, the method comprises administering to the subject a formulation comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) in an amount effective to delay the onset of the CLN2 disease or symptom in the subject.

Disclosed are a crystal of the compound (S)-N-((S)-1-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazacycloheptane-2-carboxamide salt or a salt thereof, a preparation method therefor, and the uses thereof in pharmaceutical compositions and in medicine.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a ubiquitin specific peptidase 13 inhibitor in preparation of a medicine for treating chronic kidney diseases. According to the present invention, as the acknowledged ubiquitin specific peptidase 13 inhibitor, the results of the in vivo unilateral ureteral ligation animal experiment and the in vitro TGF-beta 1 induced cell experiment show that the Spautin-1 can be used as the ubiquitin specific peptidase 13 inhibitor, the Spautin-1 can be used for alleviating UUO induced renal interstitial fibrosis, alleviating in-vitro TGF-beta1 induced renal fibroblast activation and regulating and controlling the cell cycle process of the TGF-beta1 induced renal fibroblast. The Spautin-1 has the advantages that the UUO induced renal interstitial fibrosis can be alleviated, and the in-vitro TGF-beta1 induced renal fibroblast activation can be alleviated; therefore, the Spautin-1 can relieve the CKD-related diseases and can be used for preparing the medicine for treating the CKD and the related diseases. The invention provides a new medicine source for relieving and treating CKD, and has a good clinical application prospect.

Materials, methods, and systems for enhanced protease targeting. For example, methods for the targeting of kallikrein related peptidase 2 (KLK2) are provided.

An aspect of the present invention is directed to provide a novel dipeptidyl peptidase IV (DPP-4) inhibitor and a production method thereof. The DPP-4 inhibitor according to an aspect of the present invention contains a hydrolysate obtained by hydrolyzing a protein derived from a microorganism. An article according to another aspect of the present invention for preventing and / or improving abnormality involving DPP-4 contains the DPP-4 inhibitor. A method for producing the DPP-4 inhibitor according to another aspect of the present invention includes a step of hydrolyzing a protein derived from a microorganism with a protease.

The invention relates to the technical field of biological medicines, in particular to application of dipeptidyl peptidase 3 (DPP3) as a treatment target of septicopyemia-induced myocardial injury. The invention discloses a key action mechanism of dipeptidyl peptidase 3 (DPP3) in septicopyemia induced myocardial injury, and provides a novel septicopyemia cardiomyopathy intervention strategy taking DPP3 as a target spot based on the key action mechanism. A theoretical basis and an experimental basis are provided for developing early diagnosis tools and targeted therapy drugs for septicopyemia-induced cardiomyopathy, and remarkable clinical application value and significance are achieved.

The invention relates to the first hydrolase that specifically digests the archaeal type of a peptidoglycan (PG), the major component of the cell wall of methanogens, named Talosaminidase. The enzyme consists of a signal peptide, several bacterial IG domains, a glycosyl hydrolase, several archaeal PG binding domains and a peptidase domain. The double enzymatic activity for the glycosyl hydrolase and the peptidase maximizes the lysis of archaeal cells with a cell wall of the archaeal PG-type. Engineering the enzyme by removing the signal peptide and bacterial IG domains and keeping only the archaeal PG binding, glycosyl hydrolase and peptidase made the enzyme easier to express and purify, without negatively influencing the enzymatic activity. Therefore, engineered Talosaminidase can be used to regulate populations of archaeal methanogens in the industrial, agricultural and medical settings, and consequently methane production.